Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Pertuzumab (Perjeta) - In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.

patients were allowed to receive concomitant radiotherapy and/or adjuvant hormone therapy, if indicated, according to standard therapy. 2, 3 The primary outcome was invasive disease-free survival (IDFS), measured in the intention to treat population and defined as the time from randomisation until the date of the first occurrence of one of the following events: ? ipsilateral invasive breast tumour recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion (...) receptor has been identified as an important target for the treatment of breast cancer due to its involvement in regulating cell growth, survival, and differentiation. Amplification and/or overexpression of HER2 occurs in around 15% to 20% of breast cancers and is associated with increased tumour aggressiveness, higher rates of recurrence, and increased mortality. 3 The submitting company has requested that SMC considers pertuzumab when positioned for use in patients with lymph node-positive disease

2020 Scottish Medicines Consortium

2. Pembrolizumab (Keytruda) - As monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults who

with initial evidence of disease progression until disease progression is confirmed. Patients with HNSCC should be selected for treatment based on the tumour expression of PD- L1 confirmed by a validated test. Therapy must be initiated and supervised by specialist physicians experienced in the treatment of cancer. Patients treated with pembrolizumab must be given the Patient Alert Card and be informed about the risks of pembrolizumab. Refer to the Summary of product characteristics (SPC) for further detail (...) tumour cells (=50% or <50%), p16 status (HPV status) for oropharyngeal cancers (positive or negative; participants with non-oropharyngeal tumours were considered p16-negative), and ECOG performance status score (0 or 1). Pembrolizumab was given intravenously (IV) at a dose of 200mg every 3 weeks until disease progression, intolerable toxicity, physician or participant decision, or 35 cycles, whichever occurred first. The cetuximab dose was 400mg/m² IV loading dose, then 250mg/m² IV once a week until

2020 Scottish Medicines Consortium

3. Pembrolizumab (Keytruda) - In combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.

or recurrent stage IV disease), measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and available tumour sample for biomarker assessment. They had received no previous treatment for advanced disease and had a Karnofsky performance status score of =70%. Patients were randomised equally to pembrolizumab (200mg intravenously every 3 weeks for up to 35 cycles) plus axitinib (orally 5mg twice daily continuously) or sunitinib (orally 50mg daily in 6- week cycles of 4 (...) each due to myasthenia gravis, myocarditis, necrotizing fasciitis and pneumonitis. There were seven deaths in the sunitinib 6 group due to adverse events considered to be related to study treatment: one each due to acute myocardial infarction, cardiac arrest, gastrointestinal haemorrhage, intracranial haemorrhage, hepatitis fulminant, progression of malignant neoplasm and pneumonia. 3 Summary of clinical effectiveness issues Standard first-line treatment of advanced renal cell carcinoma has been

2020 Scottish Medicines Consortium

4. Avelumab with axitinib for untreated advanced renal cell carcinoma

cell carcinoma, as with other first-line treatments renal cell carcinoma, as with other first-line treatments 3.7 The committee noted that most patients in JAVELIN Renal 101 had clear-cell disease, but in NHS practice some have non-clear-cell disease. The clinical experts stated that there is no evidence that the results in people with cancers characterised by clear-cell histology would be generalisable (or not) to people with disease characterised by non-clear-cell histology. Therefore (...) , there might be an argument to limit avelumab plus axitinib to people with clear-cell disease only. However, the clinical experts noted, and the committee agreed, that the situation is similar with other first-line treatments for advanced renal cell carcinoma. The committee agreed that this was an area in need of further research. It suggested that data should be collated by histology in the Cancer Drugs Fund, to monitor whether there is a difference in effectiveness. Indirect treatment comparison Indirect

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

5. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Full Text available with Trip Pro

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website (...) search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This trial showed that in patients with HER2-positive early breast cancer, 6 months' adjuvant trastuzumab was non-inferior to 12 months', with less cardiac toxicity and fewer severe adverse events. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . Helena Earl 1, 2, 3, * , Louise Hiller 4 , Anne-Laure Vallier 5 , Shrushma Loi 4

2020 NIHR HTA programme

6. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Full Text available with Trip Pro

[ Kerkhofs T.M. Verhoeven R.H. Van der Zwan J.M. et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013; 49 : 2579-2586 , Kebebew E. Reiff E. Duh Q.Y. et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg. 2006; 30 : 872-878 ]. Phaeochromocytomas are catecholamine-producing neuroendocrine tumours arising from chromaffin cells of the adrenal medulla or extra (...) Network for the Study of Adrenal Tumors. European Journal of Endocrinology. 2016; 175 : G1-G34 ]. Additional measurements of plasma methoxytyramine, a biomarker now increasingly available, provide useful information to assess the likelihood of malignancy [ Eisenhofer G. Lenders J.W. Siegert G. et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012; 48

2020 European Society for Medical Oncology

7. Bevacizumab (Aybintio) - various cancers

it originates in cells of a particular type (called squamous cells); • cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere; • cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment; • cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or spread to other parts of the body (...) to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes new blood vessels grow. By attaching to VEGF, Aybintio stops its effect. As a result, the cancer cannot develop its own blood supply and cancer cells are starved of oxygen and nutrients, helping to slow down the growth of tumours. What benefits of Aybintio have been shown in studies? Laboratory studies comparing Aybintio with Avastin have shown that the active substance in Aybintio is highly similar

2020 European Medicines Agency - EPARs

8. Alpelisib (Piqray) - metastatic breast cancer

Alpelisib (Piqray) - metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

9. Sonidegib (Odomzo) - basal cell carcinoma

Sonidegib (Odomzo) - basal cell carcinoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

10. Suspected cancer: recognition and referral

on the skin (particularly pearly or waxy nodules).) [2015] [2015] 1.7.6 Only consider a suspected cancer pathway referral (for an appointment within 2 weeks) for people with a skin lesion that raises the suspicion of a basal cell carcinoma if there is particular concern that a delay may have a significant impact, because of factors such as lesion site or size. [2015] [2015] 1.7.7 Follow NICE's guidance on improving outcomes for people with skin tumours including melanoma for advice on who should excise (...) of 86• finger clubbing or or • chest signs compatible with pleural disease. [2015] [2015] 1.2 1.2 Upper gastrointestinal tract cancers Upper gastrointestinal tract cancers Oesophageal cancer Oesophageal cancer 1.2.1 Offer urgent, direct access upper gastrointestinal endoscopy (to be performed within 2 weeks) to assess for oesophageal cancer in people: • with dysphagia or or • aged 55 and over with weight loss and and any of the following: - upper abdominal pain - reflux - dyspepsia. [2015] [2015

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

11. Synergo for non-muscle-invasive bladder cancer

). BCG is generally used for high-risk tumours and first-line treatment for carcinoma in situ, and the average total BCG treatment cost was $1,936 (equivalent to £1,490) per person (Sievert et al. 2009). Resource consequences Resource consequences Synergo has been used in 3 hospitals in the UK. Synergo for non-muscle-invasive bladder cancer (MIB226) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 13Costs include (...) was seen in disease-free survival when comparing RITE with the control group (HR=1.33, 95% confidence interval [CI] 0.84 to 2.10, p=0.23). There was no significant difference in the complete response Synergo for non-muscle-invasive bladder cancer (MIB226) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 13rate of carcinoma in situ at 3 months between RITE and the control group (odds ratio 0.43, 95% CI 0.18 to 1.28

2020 National Institute for Health and Clinical Excellence - Advice

12. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial

using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Groups were compared using χ 2 or Fisher's exact test. Results and limitations: Complete tumour response was seen in 33 participants (57%) in the intervention group. Fewer adverse events were reported in the intervention group than in the control group. Two patients in each group ceased instillation treatment due to adverse events. The main limitation is the current lack of long-term follow-up. Conclusions: Short (...) The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search

2020 EvidenceUpdates

13. Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial

develop into colorectal cancer (CRC). Deep learning systems allow for real-time computer-aided detection (CADe) of polyps with high accuracy. We performed a multicenter, randomized trial to assess the safety and efficacy of a CADe system in detection of colorectal neoplasias during real-time colonoscopy. Methods: We analyzed data from 685 subjects (61.32 ± 10.2 years old; 337 men) undergoing screening colonoscopies for CRC, post-polypectomy surveillance, or workup due to positive results from a fecal (...) minutes was required. Lesions were collected and histopathology findings were used as the reference standard. The primary outcome was adenoma detection rate (ADR, the percentage of patients with at least 1 histologically proven adenoma or carcinoma). Secondary outcomes were adenomas detected per colonoscopy, non-neoplastic resection rate, and withdrawal time. Results: The ADR was significantly higher in the CADe group (54.8%) than in the control group (40.4%) (relative risk [RR], 1.30; 95% confidence

2020 EvidenceUpdates

14. The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation

The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation , , , , Affiliations Expand Affiliations 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. 2 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. 3 Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. 4 Département de Médecine Générale, Université de Nantes, Nantes

2020 EvidenceUpdates

15. Effectiveness of Patient Navigation to Increase Cancer Screening in Populations Adversely Affected by Health Disparities: a Meta-analysis

Effectiveness of Patient Navigation to Increase Cancer Screening in Populations Adversely Affected by Health Disparities: a Meta-analysis Effectiveness of Patient Navigation to Increase Cancer Screening in Populations Adversely Affected by Health Disparities: a Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) of print. Effectiveness of Patient Navigation to Increase Cancer Screening in Populations Adversely Affected by Health Disparities: a Meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA. nelsonh@ohsu.edu. 2 Department of Medicine, Oregon Health & Science University, Portland, OR, USA. nelsonh@ohsu.edu. 3 Pacific Northwest

2020 EvidenceUpdates

16. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis Full Text available with Trip Pro

, Brest, France. PMID: 32654348 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Background: The Registro Informatizado de Pacientes con Enfermedad TromboEmbólica (RIETE) score and the Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) risk scores aim to identify patients with acute unprovoked venous thromboembolism (VTE) at high risk of occult cancer, but their predictive performance is unclear. Methods: The scores were (...) ), eight (5.0%) were diagnosed with cancer compared with 29 of 764 (3.8%) low-risk patients (HR, 1.2; 95% CI, 0.55-2.7). Conclusions: The predictive discriminatory performance of both scores is poor. When used dichotomously, the RIETE score is able to discriminate between low- and high-risk patients. Because this is largely driven by advanced age, these results do not support the use of these scores in daily clinical practice. Keywords: cancer; diagnosis; early detection of cancer; neoplasms; venous

2020 EvidenceUpdates

17. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

Display options Format Abstract Patients with metastatic renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and have shown limited responsiveness to inhibition of the VEGF pathway. We conducted a prespecified analysis of the randomised, phase 3 IMmotion151 trial in previously untreated patients with advanced or metastatic RCC to assess the effectiveness of atezolizumab + bevacizumab versus sunitinib in a subgroup of patients with sarcomatoid features. Patients whose tumour had (...) atezolizumab + bevacizumab achieved an objective response (49% vs 14%), including complete responses (10% vs 3%), and reported greater symptom improvements versus sunitinib. Safety was consistent with the known profiles of each drug and with that reported in the overall safety-evaluable population of IMmotion151. This analysis supports enhanced activity of atezolizumab + bevacizumab in patients with sRCC. PATIENT SUMMARY: In this report, we looked at patients with a specific type of kidney cancer (tumours

2020 EvidenceUpdates

18. Avapritinib (Ayvakyt) for the treatment of gastrointestinal stromal tumours (GIST)

Avapritinib (Ayvakyt) for the treatment of gastrointestinal stromal tumours (GIST) Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST) - Repository of AIHTA GmbH English | Browse - - - Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST) Grössmann, N. (2020): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Oncology Fact Sheet Nr. 16. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert

2020 Austrian Institute of Health Technology Assessment

19. Prostate Cancer Part 2: Follow-up in Primary Care

Treatment, Cancer Care Ontario, A Palliative Care Approach for Primary Care, HealthLinkBC – Advance Care Planning, Provincial Health Services Authority Trans Care BC – A Primary Care Toolkit – Gender-affirming Care for Trans, Two-spirit, and Gender Diverse Patients in BC, ​ ​ Diagnostic Code: 185 (malignant neoplasm of prostate) Abbreviations ACP - advance care plan ADT - androgen deprivation therapy AGREE - appraisal of guidelines for research and evaluation CBC - complete blood count CCO - Cancer Care (...) diagnosis onwards (see ). Follow-up Prostate Cancer Care Primary care practitioners provide an essential role for the continuity of patient care in all settings, both directly and through the coordination of care with other health care professionals. This reduces the fragmentation of care, improves patient safety, and enhances the overall quality of patient care. PSA Testing for Surveillance of Recurrent Disease In the absence of specific evidence to guide prostate-specific antigen (PSA) testing

2020 Clinical Practice Guidelines and Protocols in British Columbia

20. Prostate Cancer Part 1: Diagnosis and Referral in Primary Care

Cancer Tips, Advice, and Support – Prostate Centre Canada – Canadian Cancer Society – Diagnostic Code: 185 (malignant neoplasm of prostate) Abbreviations CCO - Cancer Care Ontario DRE - digital rectal exam ERSPC - European Randomized Study of Screening for Prostate Cancer LUTS - lower urinary tract symptoms PSA - prostate specific antigen This guideline is based on scientific evidence current as of November 2017 (refer to Methodology ). The guideline was developed by the BC Cancer Primary Care (...) the age of 60 when they are diagnosed and most men will survive their prostate cancer. It is estimated that 1 in 29 men who are diagnosed with prostate cancer would be expected to die of the disease. The following risk factors are associated with an increased risk of prostate cancer and should be considered when assessing men who present with symptoms or with questions about testing: Men of African descent. Family history of prostate cancer (paternal side; first-degree relatives (i.e., father

2020 Clinical Practice Guidelines and Protocols in British Columbia